- Home
- WLKP vs DNTH Comparison
WLKP vs DNTH Comparison
Compare WLKP & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLKP
- DNTH
- Stock Information
- Founded
- WLKP 2014
- DNTH 2015
- Country
- WLKP United States
- DNTH United States
- Employees
- WLKP N/A
- DNTH N/A
- Industry
- WLKP Major Chemicals
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- WLKP Industrials
- DNTH Health Care
- Exchange
- WLKP Nasdaq
- DNTH Nasdaq
- Market Cap
- WLKP 817.5M
- DNTH 724.8M
- IPO Year
- WLKP 2014
- DNTH N/A
- Fundamental
- Price
- WLKP $23.40
- DNTH $16.87
- Analyst Decision
- WLKP
- DNTH Strong Buy
- Analyst Count
- WLKP 0
- DNTH 8
- Target Price
- WLKP N/A
- DNTH $54.33
- AVG Volume (30 Days)
- WLKP 22.2K
- DNTH 424.0K
- Earning Date
- WLKP 04-30-2025
- DNTH 05-08-2025
- Dividend Yield
- WLKP 8.13%
- DNTH N/A
- EPS Growth
- WLKP 14.91
- DNTH N/A
- EPS
- WLKP 1.77
- DNTH N/A
- Revenue
- WLKP $1,135,896,000.00
- DNTH $6,235,000.00
- Revenue This Year
- WLKP $8.90
- DNTH N/A
- Revenue Next Year
- WLKP $6.87
- DNTH N/A
- P/E Ratio
- WLKP $13.10
- DNTH N/A
- Revenue Growth
- WLKP N/A
- DNTH 120.63
- 52 Week Low
- WLKP $21.19
- DNTH $15.89
- 52 Week High
- WLKP $25.04
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- WLKP 47.85
- DNTH 35.41
- Support Level
- WLKP $23.00
- DNTH $16.44
- Resistance Level
- WLKP $23.45
- DNTH $18.64
- Average True Range (ATR)
- WLKP 0.31
- DNTH 1.74
- MACD
- WLKP 0.01
- DNTH -0.30
- Stochastic Oscillator
- WLKP 60.61
- DNTH 14.67
About WLKP Westlake Chemical Partners LP Common Units representing limited partner interests
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.